SOURCE: Matinas BioPharma Holdings, Inc.

September 05, 2013 08:00 ET

Matinas BioPharma Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10, 2013

Company Will Present on Monday, September 9 at 4:55 p.m. ET

TARPON SPRINGS, FL--(Marketwired - September 05, 2013) - Matinas BioPharma Holdings, Inc., an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular conditions, announced today that it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.

Roelof Rongen, Matinas BioPharma's Chief Executive Officer will provide an overview of the Company's business during the live presentation on Monday, September 9, 2013 at 4:55 p.m. ET and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

About Rodman & Renshaw Conferences, LLC
The Rodman & Renshaw Annual Global Investment Conference is an informational service and networking opportunity for companies and investors. Rodman does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Rodman soliciting any offers to buy or sell any security of any company.

About Matinas BioPharma
Matinas BioPharma Holdings, Inc. is an early stage privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of cardiovascular conditions. The Company's lead product candidate, MAT9001, is designed for treatment of severe hypertriglyceridemia (TG>500 mg/dl) and mixed dyslipidemia (TG 200-499 mg/dl while on statin therapy). The Matinas BioPharma management team brings a cumulative multi-decade omega-3 pharmaceutical experience to the Company, providing a unique perspective and capability for the development of the next generation of omega-3-fatty acid-based pharmaceutical products.

For more information, please visit www.matinasbiopharma.com.

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from studies and clinical trials involving MAT9001 or other product candidates. Matinas BioPharma also faces risks related to its ability to enroll patients in studies and may need to modify or delay these studies. As a result, MAT9001 may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to Matinas BioPharma and the Company assumes no obligation to update any such forward-looking statements.

Contact Information

  • Investor and Media Conact
    Jenene Thomas
    Jenene Thomas Communications, LLC
    Investor Relations and Corporate Communications Advisor
    Phone: +1 (908) 938-1475
    Email: Jthomas@matinasbiopharma.com